nach oben

Clinical and Translational Oncology

Erschienen in:

11.08.2023 | RESEARCH ARTICLE

Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma

verfasst von: Jielang Li, Chen Huang, Xin Wang, Zhiping Li, Yali Shen

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the efficacy and safety of capecitabine/cisplatin (XP) combined with intensity-modulated radiation therapy (IMRT) in patients with non-metastatic anal squamous cell carcinoma (ASCC).

Method and materials

All patients with ASCC who received radical concurrent chemoradiotherapy in the past 8 years were screened. Patients who received XP or mitomycin/5-fluorouracil (MF) were selected and analyzed retrospectively.

Results

ASCC is an uncommon cancer, there were 36 patients were included in our study. The XP group and MF group included 18 patients each. The clinical complete response (cCR) rates in the XP group and the MF group were 94.4% and 88.9%, respectively (P = 1). The 2-year local control (LC), disease-free survival (DFS), and colostomy-free survival (CFS) rates were higher in the XP group than in the MF group (100% vs 93.3%, P = 0.32). Hematologic toxicities, especially grade ≥ 3 leukopenia (11.1% vs 44.4%, P = 0.06) and neutropenia (5.6% vs 61.1%, P = 0.001), were lower in the XP group than MF group. As a result of fewer side effects, fewer patients in the XP group demanded the dose reduction of chemotherapy (11.1% vs 50%, P = 0.03) and radiation interruption (55.6% vs 77.8%, P = 0.289). Delayed radiotherapy was shorter in the XP group (2.5 vs 6.5 days, P = 0.042) than in the MF group.

Conclusion

The XP regimen was as effective as the MF regimen in non-metastatic ASCC. Compared with the standard MF regimen, XP combined with IMRT showed higher treatment completion and lower toxicities. It could be considered a feasible alternative for patients with non-metastatic ASCC.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer Stat Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRef

Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol. 2017;46(3):924–38. https://doi.org/10.1093/ije/dyw276.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics. Cancer J Clin. 2018. https://doi.org/10.3322/caac.21442.CrossRef

Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17(3):354–6. https://doi.org/10.1007/bf02586980.CrossRefPubMed

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party UK Co-ordinating Committee on Cancer Research. Lancet 348: 1049–1054

Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15(5):2040–9. https://doi.org/10.1200/jco.1997.15.5.2040.CrossRefPubMed

Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21. https://doi.org/10.1001/jama.299.16.1914.CrossRefPubMed

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–24. https://doi.org/10.1016/s1470-2045(13)70086-x.CrossRefPubMed

Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527–39. https://doi.org/10.1200/jco.1996.14.9.2527.CrossRefPubMed

10.

Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(35):4344–51. https://doi.org/10.1200/jco.2012.43.8085.CrossRef

11.

Doci R, Zucali R, La Monica G, Meroni E, Kenda R, Eboli M, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(12):3121–5. https://doi.org/10.1200/jco.1996.14.12.3121.CrossRef

12.

Peiffert D, Seitz JF, Rougier P, François E, Cvitkovic F, Mirabel X, et al. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncology Off J Eur Soc Med Oncol. 1997;8(6):575–81. https://doi.org/10.1023/a:1008295119573.CrossRef

13.

Souza KT, Pereira AA, Araujo RL, Oliveira SC, Hoff PM, Riechelmann RP. Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis. Ecancermedicalscience. 2016;10:699. https://doi.org/10.3332/ecancer.2016.699.CrossRefPubMedPubMedCentral

14.

Oliveira SC, Moniz CM, Riechelmann R, Alex AK, Braghirolli MI, Bariani G, et al. Phase II Study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2016;47(1):75–81. https://doi.org/10.1007/s12029-015-9790-4.CrossRefPubMed

15.

Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014;111(9):1726–33. https://doi.org/10.1038/bjc.2014.467.CrossRefPubMedPubMedCentral

16.

Rotundo MS, Zampino MG, Ravenda PS, Bagnardi V, Peveri G, Dell’Acqua V, et al. Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. Therapeutic Adv in Med Oncol. 2020;12:1758835920940945. https://doi.org/10.1177/1758835920940945.CrossRef

17.

Li J, Xu H, Zou J, Wang X, Li Z, Shen Y. Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study. Scand J Gastroenterol. 2021;56(4):432–6. https://doi.org/10.1080/00365521.2021.1879250.CrossRefPubMed

18.

Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824–30. https://doi.org/10.1016/j.ijrobp.2008.08.070.CrossRefPubMed

19.

Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33. https://doi.org/10.1016/j.ijrobp.2012.09.023.CrossRefPubMed

20.

Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455–62. https://doi.org/10.1016/j.ijrobp.2011.12.058.CrossRefPubMed

21.

Tchelebi LT, Eng C, Messick CA, Hong TS, Ludmir EB, Kachnic LA, et al. Current treatment and future directions in the management of anal cancer. CA Cancer J Clin. 2022;72(2):183–95. https://doi.org/10.3322/caac.21712.CrossRefPubMed

22.

Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017;18(3):347–56. https://doi.org/10.1016/s1470-2045(17)30071-2. CrossRefPubMedPubMedCentral

23.

Vieillot S, Fenoglietto P, Lemanski C, Moscardo CL, Gourgou S, Dubois JB, et al. IMRT for locally advanced anal cancer: clinical experience of the montpellier cancer center. Radiat Oncol. 2012;7:45. https://doi.org/10.1186/1748-717x-7-45.CrossRefPubMedPubMedCentral

24.

Janssen S, Glanzmann C, Bauerfeind P, Stieb S, Studer G, Brown M, et al. Clinical experience of SIB-IMRT in anal cancer and selective literature review. Radiation Oncol. 2014;9:199. https://doi.org/10.1186/1748-717x-9-199.CrossRef

25.

Peixoto RD, Wan DD, Schellenberg D, Lim HJ. A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. J Gastrointest Oncol. 2016;7(4):665–72. https://doi.org/10.21037/jgo.2016.06.04.CrossRefPubMedPubMedCentral

26.

Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of radiation therapy oncology group trials 87–04 and 98–11. J Clin Oncol. 2010;28(34):5061–6. https://doi.org/10.1200/jco.2010.29.1351.CrossRefPubMedPubMedCentral

27.

Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol. 2007;13(6):895–900. https://doi.org/10.3748/wjg.v13.i6.895.CrossRefPubMedPubMedCentral

28.

Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008;51(2):147–53. https://doi.org/10.1007/s10350-007-9125-z.CrossRefPubMed

29.

Raphael MJ, Ko G, Booth CM, Brogly SB, Li W, Kalyvas M, et al. Factors associated with chemoradiation therapy interruption and noncompletion among patients with squamous cell anal carcinoma. JAMA Oncol. 2020;6(6):881–7. https://doi.org/10.1001/jamaoncol.2020.0809.CrossRefPubMed

30.

Almaazmi H, Taylor JP, Stem M, Yu D, Lo BD, Safar B, et al. Anal squamous cell carcinoma: radiation therapy alone must be avoided. J Surg Res. 2020;247:530–40. https://doi.org/10.1016/j.jss.2019.09.049.CrossRefPubMed

Titel: Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma
verfasst von: Jielang Li
Chen Huang
Xin Wang
Zhiping Li
Yali Shen
Publikationsdatum: 11.08.2023
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 3/2024
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03296-1

Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

RESEARCH ARTICLE

Palliative care for children with central nervous system tumors: results of a Spanish multicenter study

RESEARCH ARTICLE

Development of fatty acid metabolism score based on gene signature for predicting prognosis and immunotherapy response in colon cancer

RESEARCH ARTICLE

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

RESEARCH ARTICLE

The impact of boost radiation therapy after hysterectomy on cervical cancer patients with close or positive resection margins

RESEARCH ARTICLE

Nephrectomy and IVC thrombectomy in renal cancer: a narrative review

REVIEW ARTICLE

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma